reuters lilly - Search News

Eli Lilly to buy Boston's Kelonia for up to $7 billion

Eli Lilly to buy Boston's Kelonia for up to $7 billion in cancer push

U.S. drugmaker Eli Lilly (LLY.N) will buy privately held biotech firm Kelonia Therapeutics ‌for up to $7 billion, gaining access to experimental cancer treatments as it bolsters its oncology pipeline.

· 1d

Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

· 1d

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

· 12h

Eli Lilly Strikes Deal for Cancer Biotech

Eli Lilly LLY 2.55% is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, according to people familiar with the matter.

· 18h

Eli Lilly Announces $7 Billion Deal. What It Means for the Stock.

24/7 Wall St · 16h

Live Nasdaq Composite: Markets Mixed on Mideast Uncertainty as Apple Captures $4T Market Cap

3don MSN

Lilly CEO sees weight-loss drugs reaching about half of potential users at peak

By Leah Douglas WASHINGTON, April 17 (Reuters) - Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems and financial constraints,

Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial

April 16 () - Eli Lilly said on Thursday its newly approved obesity ‌pill helped reduce the risk ‌of major cardiovascular events at a similar rate as insulin glargine in adults with type 2 diabetes and obesity,